David M. Irlbeck - Concepedia

Concepedia

Author

David M. Irlbeck

GlaxoSmithKline (United States)ORCID

Also Known As

Browne, Edward P., D Irlbeck, D M Irlbeck, D. Irlbeck, D.M. Irlbeck, David Irlbeck, David M Irlbeck, David M. Irlbeck, Irlbeck, David M., Sutton, Cameron

30

Publications

1.5K

Citations

16

H-Index

36

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation University of North Carolina at Chapel Hill Duke University Hospital McGill University Health Centre

DM

About

David M. Irlbeck is an author at GlaxoSmithKline (United States) specializing in immunology, medicine, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	659
2	Natural Sciences	2	2	53
3	Allergy	1	1	122
4	Biochemistry	1	1	20
5	Biomolecular Engineering	1	1	53

David M. Irlbeck

×

19

Publications

1.5K

Citations

16

H-Index

	Year	Citations
Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy Jeffrey A. Johnson, LI Jin-fen, Xierong Wei, PLoS Medicine	2008	372
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo Christopher C. Nixon, Maud Mavigner, Gavin C. Sampey, Nature Viral PersistenceHuman RetrovirusImmunodeficienciesImmune RegulationImmunology	2020	311
Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles Nancy Davis, Ian J. Caley, Kevin Brown, Journal of Virology	2000	201
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector Ian J. Caley, Michael R. Betts, David M. Irlbeck, Journal of Virology Baby Hamster KidneyVeterinary VaccineImmunologyViral PathogenesisVee Vector	1997	122
Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine John Bartlett, Judy Johnson, Gisela Herrera, JAIDS Journal of Acquired Immune Deficiency Syndromes	2006	73
Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors Terri Watkins, Wolfgang Resch, David M. Irlbeck, Antimicrobial Agents and Chemotherapy ImmunologyMolecular BiologySelective PressureAntiviral DrugDrug Resistance	2003	53
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens ER Lanier, Naomi Givens, Christopher Stone, HIV Medicine	2004	40
Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth Tomas Raul Wiche Salinas, Yuwei Zhang, Daniele Sarnello, Proceedings of the National Academy of Sciences	2021	40
Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles Nancy Davis, Ian J. Caley, Kevin Brown, Journal of Virology VaccinationVeterinary VaccineVaccine DevelopmentImmunologyAntiviral Response	2000	34
Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity Gavin J. Henderson, Sook-Kyung Lee, David M. Irlbeck, Antimicrobial Agents and Chemotherapy Viral ReplicationHiv-1 ProteaseNatural SciencesHuman RetrovirusInhibitor Sensitivity	2011	33

Page 1